Wnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia

Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy

(2015) Jean-Claude Chomel et al.   Oncotarget

A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line

(2012) Stephany Correa et al.   Proteome Science

Chronic Myeloid Leukemia Stem Cell Biology

(2012) Leslie A. Crews et al.   Current Hematologic Malignancy Reports

Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib

(2011) T. P. Stromskaya et al.   BIOCHEMISTRY-MOSCOW

Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease

(2011) J.-C. Chomel et al.   BLOOD

Managing resistance in chronic myeloid leukemia

(2011) Sameek Roychowdhury et al.   BLOOD REVIEWS

Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1

(2011) Osamu Yamada et al.   CELLULAR SIGNALLING

CML biology for the clinician in 2011: six impossible things to believe before breakfast on the way to cure

(2011) B. Leber   Current Oncology

Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways

(2011) Carine Tang et al.   LEUKEMIA & LYMPHOMA

Wnt/Ca2+/NFAT Signaling Maintains Survival of Ph+ Leukemia Cells upon Inhibition of Bcr-Abl

(2010) Mark A. Gregory et al.   CANCER CELL

Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients

(2010) Flavia C. Vasconcelos et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Chronic myeloid leukemia: mechanisms of blastic transformation

(2010) Danilo Perrotti et al.   JOURNAL OF CLINICAL INVESTIGATION

Critical molecular pathways in cancer stem cells of chronic myeloid leukemia

(2010) Y Chen et al.   LEUKEMIA

Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients withde novochronic myelogenous leukemia: the role of different cell types

(2010) Zdenek Racil et al.   LEUKEMIA & LYMPHOMA

Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia

(2010) Margherita Maffioli et al.   LEUKEMIA RESEARCH

Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia

(2010) Ling-Na Ni et al.   MEDICAL ONCOLOGY

Targeting Chronic Myeloid Leukemia Stem Cells

(2010) G. Vignir Helgason et al.   Current Hematologic Malignancy Reports

Advances in the biology and therapy of patients with chronic myeloid leukaemia

(2009) Elias Jabbour et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia

(2009) D. H. Kim et al.   CLINICAL CANCER RESEARCH

The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/β-catenin pathway

(2009) M Flahaut et al.   ONCOGENE

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia

(2008) S. Dulucq et al.   BLOOD

Hyaluronan-mediated CD44 Interaction with p300 and SIRT1 Regulates β-Catenin Signaling and NFκB-specific Transcription Activity Leading to MDR1 and Bcl-xLGene Expression and Chemoresistance in Breast Tumor Cells

(2008) Lilly Y. W. Bourguignon et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

β-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia

(2008) Y Hu et al.   LEUKEMIA